Company Overview - Krystal Biotech, Inc. (KRYS) shares increased by 4.2% to close at $143.67, with trading volume significantly higher than usual, reflecting a 10.3% gain over the past four weeks [1][2] Product Development - The stock price surge followed the initiation of patient dosing in the phase III IOLITE study for KB803 eye drops, targeting DEB-related corneal damage, which is a next-generation version of the approved gene therapy Vyjuvek [2] - KB803 addresses a rare patient population lacking corrective treatments, and the decentralized, at-home study design, along with prior compassionate use data showing strong efficacy, has bolstered investor confidence [2] Financial Performance Expectations - The company is projected to report quarterly earnings of $1.31 per share, reflecting a year-over-year increase of 52.3%, with revenues expected to reach $102.5 million, up 45.9% from the previous year [3] - The consensus EPS estimate for the quarter has remained stable over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Krystal Biotech is categorized under the Zacks Medical - Biomedical and Genetics industry, where Coherus Oncology (CHRS) also operates, having closed 5.6% higher at $0.77, but with a -3.9% return over the past month [5] - Coherus Oncology's consensus EPS estimate for the upcoming report is -$0.25, representing a significant year-over-year decline of 78.6% [6]

Core Viewpoint - Paychex reported quarterly earnings of $1.19 per share, exceeding the Zacks Consensus Estimate of $1.18 per share, and showing an increase from $1.12 per share a year ago, indicating a positive earnings surprise of +0.85% [1] Financial Performance - The company achieved revenues of $1.43 billion for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 0.87% and up from $1.3 billion year-over-year [2] - Over the last four quarters, Paychex has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Paychex shares have increased approximately 8.6% since the beginning of the year, outperforming the S&P 500's gain of 3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.22 on revenues of $1.56 billion, and for the current fiscal year, it is $5.38 on revenues of $6.58 billion [7] - The outlook for the Internet - Software industry, where Paychex operates, is favorable, ranking in the top 22% of over 250 Zacks industries, suggesting potential for outperformance [8]

Company Overview - Amarin (AMRN) shares increased by 27.3% to close at $16.04, with notable trading volume compared to typical sessions, and a 13.4% gain over the past four weeks [1][2] Recent Developments - Amarin licensed EU rights to its drug Vazkepa to Recordati, an Italy-based company, for $25 million upfront, with potential milestones of up to $150 million and ongoing royalties, significantly expanding Vazkepa's market reach and reducing EU-related costs by an expected $70 million over the next 12 months [2] Financial Performance - The company is expected to report a quarterly loss of $0.60 per share, a year-over-year change of -400%, with revenues projected at $45.19 million, down 33% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 22.4% higher over the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Amarin is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like MannKind (MNKD), which saw a 5.1% increase in its last trading session [5] - MannKind's consensus EPS estimate has remained unchanged at $0.04, reflecting a -20% change from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [6]

Core Insights - Progress Software (PRGS) is expected to report quarterly earnings of $1.30 per share, reflecting a 19.3% increase year over year, with revenues projected at $237.84 million, indicating a 35.9% year-over-year growth [1] - The consensus EPS estimate has remained stable over the last 30 days, suggesting analysts have not changed their initial earnings projections during this period [1][2] Revenue Estimates - Analysts predict 'Revenue- Services' will reach $52.70 million, representing a significant year-over-year increase of 183.4% [4] - The 'Revenue- Maintenance' is expected to be approximately $111.65 million, indicating an 8.9% increase from the previous year [4] - 'Revenue- Maintenance and services' is forecasted to total $167.92 million, reflecting a 38.7% year-over-year growth [4] - 'Revenue- Software licenses' is anticipated to be $70.20 million, showing a 30.1% increase compared to the same quarter last year [5] Stock Performance - Shares of Progress Software have increased by 4.4% over the past month, slightly underperforming the Zacks S&P 500 composite, which rose by 5.1% [6] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the overall market in the near term [6]

Company Overview - Capricor Therapeutics (CAPR) shares increased by 20.4% to $9.25 in the last trading session, following a period of 25.1% loss over the past four weeks, indicating a significant recovery in stock performance [1] - The company is focused on developing Deramiocel, a cell therapy candidate aimed at treating Duchenne Muscular Dystrophy-associated cardiomyopathy [2] Regulatory Updates - Capricor provided positive regulatory updates regarding its Biologics License Application (BLA) for Deramiocel, with the FDA indicating that an Advisory Committee meeting is not required at this time [2] - The BLA is currently under Priority Review, with a target action date set for August 31, 2025, which may enhance investor confidence [2] Financial Performance Expectations - The company is expected to report a quarterly loss of $0.43 per share, reflecting a year-over-year decline of 22.9% [3] - Revenue projections for the upcoming quarter are estimated at $2.89 million, down 27.2% compared to the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for Capricor has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - The stock's price movement is typically correlated with trends in earnings estimate revisions, indicating that future price strength may depend on any changes in these estimates [4] Industry Context - Capricor operates within the Zacks Medical - Products industry, which includes other companies such as Myomo, Inc. (MYO) [4] - Myomo's consensus EPS estimate has seen a significant change of -23.5% over the past month, indicating potential challenges within the same industry [5]

Core Viewpoint - MicroStrategy's stock performance has been under scrutiny, with recent trends indicating a potential for growth or decline based on earnings estimates and revenue projections [1][2]. Earnings Estimate Revisions - For the current quarter, MicroStrategy is expected to report a loss of $0.12 per share, reflecting an increase of +84.2% compared to the same quarter last year [5]. - The consensus earnings estimate for the current fiscal year is -$15.73, indicating a significant year-over-year decline of -134.1% [5]. - For the next fiscal year, the consensus earnings estimate is $0.4, which represents a growth of +97.5% from the previous year [6]. - MicroStrategy holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [7]. Revenue Growth Forecast - The consensus sales estimate for the current quarter is $112.15 million, showing a year-over-year increase of +0.6% [11]. - For the current fiscal year, the sales estimate is $466.5 million, indicating a growth of +0.7%, while the next fiscal year is projected at $484.8 million, reflecting a +3.9% change [11]. Last Reported Results and Surprise History - In the last reported quarter, MicroStrategy generated revenues of $111.07 million, which is a decrease of -3.6% year-over-year [12]. - The reported EPS was -$16.49, compared to -$0.83 a year ago, with a revenue surprise of -4.01% against the Zacks Consensus Estimate [12]. - Over the last four quarters, MicroStrategy has surpassed consensus EPS estimates multiple times and has also exceeded revenue estimates during this period [13]. Valuation - MicroStrategy is currently graded F on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17]. - Valuation metrics such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued or undervalued [15][16].

Core Viewpoint - General Mills reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, but down from $1.01 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was +4.23%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter were $4.56 billion, missing the Zacks Consensus Estimate by 1.04%, and down from $4.71 billion year-over-year [3] - The company has topped consensus revenue estimates twice in the last four quarters [3] Stock Performance - General Mills shares have declined approximately 16.3% year-to-date, contrasting with the S&P 500's gain of 3.6% [4] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.94 on revenues of $4.62 billion, and for the current fiscal year, it is $3.87 on revenues of $18.95 billion [8] - The estimate revisions trend for General Mills was unfavorable prior to the earnings release, which may impact future stock performance [7] Industry Context - The Food - Miscellaneous industry, to which General Mills belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, suggesting potential challenges ahead [9] - Comparatively, Lamb Weston, another company in the same industry, is expected to report a year-over-year earnings decline of -16.7% [10]

In the latest close session, Spotify (SPOT) was up +2.57% at $749.91. The stock outpaced the S&P 500's daily gain of 1.11%. Elsewhere, the Dow saw an upswing of 1.19%, while the tech-heavy Nasdaq appreciated by 1.43%. The stock of music-streaming service operator has risen by 11.83% in the past month, leading the Computer and Technology sector's gain of 5.67% and the S&P 500's gain of 3.92%.The upcoming earnings release of Spotify will be of great interest to investors. It is anticipated that the company wi ...

Core Viewpoint - New Gold (NGD) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, particularly influenced by institutional investors [4]. - Rising earnings estimates for New Gold suggest an improvement in the company's underlying business, which could lead to higher stock prices as investors respond positively [5]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - New Gold's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions for New Gold - For the fiscal year ending December 2025, New Gold is expected to earn $0.42 per share, consistent with the previous year's figure [8]. - Over the past three months, the Zacks Consensus Estimate for New Gold has increased by 83.7%, reflecting a significant upward revision in earnings expectations [8].

HudBay Minerals (HBM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings p ...